Psoriasis (plaque psoriasis)
Conditions
Interventions
Dose reduction strategy
Sponsors
ZonMw, KCE
Eligibility
Inclusion criteria
Inclusion criteria: • Plaque psoriasis (primarily) • Treatment for 6 months at least with IL23 or IL17 inhibitor in a normal dose (dose advised by the label) • PASI= 5 at inclusion and in previous 6 months (in previous 6 months, it should be clear from the patient record that psoriasis was clear/almost clear if no PASI scores are available). • DLQI = 5 at inclusion
Exclusion criteria
Exclusion criteria: • Another indication than plaque psoriasis as the main indication for biologic use (e.g. receives biologic for rheumatoid arthritis as the main indication). • Concomitant use of systemic immunosuppressants other than methotrexate or acitretin (e.g. prednisone, cyclosporine etc). • Severe comorbidities with short life-expectancy (e.g. metastasized tumour). • Presumed inability to follow the study protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cumulative incidence of persistent flares (PASI> 5 for = 3 months) | — |
Secondary
| Measure | Time frame |
|---|---|
| The percentage of successful dose reductions, the course of disease activity (PASI), incidence of short disease flares (PASI> 5 once), course of disease-related quality of life (DLQI), predictors for successful dose reduction, side effects, antibody formation and trough levels of biologics (PK), health-status (SF-36), quality-adjusted life-years (EQ-5D-5L), volumes of care (iMTA Medical Consumption Questionnaire), loss of productivity and presenteeism (Productivity Cost Questionnaire). | — |
Contacts
Public ContactJuul van den Reek
Radboudumc
Outcome results
None listed